Niva Bupa Health Insurance Company Ltd, a listed standalone health insurer, has received a Show Cause Notice (SCN) from the Insurance Regulatory and Development Authority of India (IRDAI) following an inspection conducted in February 2025. According to reports from CNBC TV18 and ScanXNews, the company disclosed this development in an exchange filing on February 27, 2026. IRDAI issued the SCN on February 26, 2026 at 1751 Hrs (IST) via email, in relation to business and operational aspects of the company, with Niva Bupa stating it is 'in the process of submitting its response' to the regulator. The regulatory action stems from violations of certain provisions under IRDAI's Master Circular on Health Insurance Business, Master Circular on Protection of Policyholders' Interest, and Master Circular on Corporate Governance.
The Letter of Advice issued by IRDAI flagged violations of certain provisions under multiple regulatory frameworks. As reported by CNBC TV18 and ScanXNews, the violations were identified under IRDAI's Master Circular on Health Insurance Business, Master Circular on Protection of Policyholders' Interest, and Master Circular on Corporate Governance. The company confirmed it is 'in the process of implementing necessary actions' as advised in the letter, with no current impact on operations. The regulatory action follows IRDAI's inspection during February 2025, during which the company had previously provided observations that were duly replied to by the company.
According to the company's filing, 'there is no impact on financial, operation or other activities of the Company arising therefrom at this stage'. Niva Bupa has requested the exchanges to take the information on record and confirmed that it is 'cooperating with the regulator and will respond to the notice in due course'. The insurer has enclosed the required disclosures under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, with Company Secretary and Compliance Officer Aparna Sharma signing the disclosure, confirming the details provided are 'true, correct and complete to the best of our knowledge and belief'. The company emphasized that there is 'no impact on financial, operational, or other activities arising from this regulatory action at this stage'.
Shares of Niva Bupa closed today's trading session 2.3% lower at ₹74.69 on the NSE, as reported by CNBC TV18. The company has clarified that there is 'no impact on financial, operation or other activities of the Company arising therefrom at this stage' from the regulatory action, indicating the market's concern about the potential implications of the inspection findings. The stock has shown mixed performance with -1.82% in one day, -1.29% over 5 days, -2.48% in one month, -9.93% over 6 months, but +1.86% over one year and +1.45% over 5 years, according to ScanXNews data.
